The selectivity of statin action toward PAR-2, a receptor overexpressed in colorectal malignancies and associated with tumour progression, drug resistance, and poor prognosis, prompted us to interrogate the downstream functional consequences of this inhibition. Here, F2RL1 is linked to neoplasm.